Yanely Pineiro Puebla, MD
Internal Medicine · Pembroke Pines, FLNPI 1750702189
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.3% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $390 and has fallen 67.2% since, to $128 in 2025.
Across 40 payments — averaging $31.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$283
- Novartis$149
- Galderma Laboratories, L.p.$125
- Novo Nordisk$107
- Johnson & Johnson$94
- Redhill Biopharma Inc.$72
- plus $428 from 11 others
Across 311 payments — averaging $39,832 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$10.7M
- E.r. Squibb & Sons, L.L.C.$1.5M
- Merck$159K
- Amgen$26K
- AbbVie$18K
- Sanofi US Services Inc.$17K
- plus $4K from 1 others
What the payments were for
- Speaking & faculty fees$726%
- Food & beverage$1,18694%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 3 | $283 |
| Novartis | 8 | $149 |
| Galderma Laboratories, L.p. | 1 | $125 |
| Novo Nordisk | 5 | $107 |
| Johnson & Johnson | 1 | $94 |
| Redhill Biopharma Inc. | 1 | $72 |
| Bayer | 3 | $66 |
| Vivus LLC | 3 | $63 |
| Sanofi-aventis U.S. LLC | 2 | $49 |
| Exact Sciences | 2 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $41 |
| GSK | 2 | $36 |
| Pfizer | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Genentech USA, Inc. | 2 | $23 |
| Eisai Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veklury$240
How this compares
$1,258 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 46 | $33,483 |
| EntrestoSacubitril/Valsartan | 24 | $15,087 |
| FarxigaDapagliflozin Propanediol | 15 | $9,790 |
| MyrbetriqMirabegron | 11 | $5,002 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $1,818 |
| Olanzapine | 13 | $1,019 |
| Nifedipine ErNifedipine | 42 | $905 |
| Valsartan | 12 | $821 |
| Oxybutynin Chloride | 25 | $633 |
| Famotidine | 44 | $597 |
| Gabapentin | 73 | $579 |
| Omeprazole | 69 | $562 |
| Atorvastatin Calcium | 63 | $529 |
| Levothyroxine Sodium | 61 | $468 |
| Pantoprazole Sodium | 75 | $441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $35 | $33,48346 claims |
| NovartisEntresto | $149 | $15,08724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Pembroke Pines
- Manuel GonzalezPembroke Pines$37K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.